Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3/5
Hugel Inc (145020 KS)
Watchlist
57
Analysis
Health Care
•
South Korea
Hugel, Inc. is a Bio-pharmaceutical company that focuses on developing beauty/cosmetics related products. The Company's main products include botulinum toxin and fillers.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hugel Inc
•
09 Nov 2024 07:14
Hugel Inc (145020 KS): Record High Quarterly Sales and Operating Profit in 3Q; US Launch to Start
​Hugel achieved revenue and operating profit of KRW105B and KRW53B in 3Q24, up 24% and 55%, YoY, respectively. The company plans to officially...
Tina Banerjee
Follow
503 Views
Share
bullish
•
Thematic (Sector/Industry)
•
21 Dec 2023 01:30
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
Tina Banerjee
Follow
714 Views
Share
bullish
•
Cosmax Inc
•
06 Aug 2025 09:42
Korean Government Confirms Visa-Free Entry of Group Tourists from China to South Korea
We provide a list of top 20 companies in Korea that are key beneficiaries of the no visa policy for group tour visitors from China to South Korea.
Douglas Kim
Follow
299 Views
Share
bullish
•
Thematic (Sector/Industry)
•
03 Aug 2025 00:30
APAC Healthcare Weekly (Aug 3)– Celltrion, Alteogen, Wuxi Bio, CSPC, Jiangsu Hengrui, Eisai, Kissei
Celltrion is acquiring a biopharmaceutical production plant in US. Wuxi Bio starts construction of new facility. CSPC and Jiangsu Hengrui stuck...
Tina Banerjee
Follow
338 Views
Share
bullish
•
Thematic (Sector/Industry)
•
22 Jun 2025 00:30
APAC Healthcare Weekly (June 22)- Samsung Biologics, Daewoong Pharma, Shionogi, Simcere, CSL
Samsung Bio launches new service for early-stage biotechs. Shionogi’s tender offer for Torii becomes successful. Simcere stuck outlicensing deal....
Tina Banerjee
Follow
437 Views
Share
Previous
1
2
3
4
5
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.56.4
x